Drug companies have formed a new group to present lawmakers with research on what the industry sees as the negative impacts ...

Federal judges in Texas and Connecticut on Thursday ruled against arguments challenging the constitutionality of the Medicare ...

Pharmaceutical companies were dealt back-to-back blows over the last 24 hours in their fight against the Biden-era Medicare ...

Three federal courts reject legal challenges to Medicare drug price negotiation Judges side with government in cases filed by ...

The drug industry’s top lobbying group is appealing its latest loss in its challenge to Medicare’s Drug Price Negotiation ...

Little-known provisions in the Big Beautiful Bill lobbied by industry will cost Medicare billions in missed savings.

The negotiated drugs include those that are frequently dispensed as well as those that are the most expensive.

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Pharma industry loses on Medicare price ...

Three years after President Joe Biden signed the Inflation Reduction Act, the Trump administration has significantly reduced ...

Our Drug Pricing and Market Access team tracks recent developments in healthcare reform, the Medicaid Drug Rebate Program, the 340B Program, ...

All other drugs listed cost the program under $2 billion. Medicare Part D spent the least on Otezla at $995 million, with 31,000 enrollees who used that medication, according to the fact sheet.

The Trump administration is planning a five-year test allowing states to cover weight-loss drugs like Ozempic and Wegovy under Medicare and Medicaid programs.